Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Date first appeared online | 05/01/2020 |
DOI | 10.1111/dom.13955 |
Authors | Bain S. |
Journal Name | Diabetes, Obesity and Metabolism |
Volume | 22 |
Documents
- 53094.pdf , Book, Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC).